



11) Publication number:

0 097 374
A2

12) **EUROPEAN PATENT APPLICATION**

21) Application number: 83106113.0

61) Int. Cl.³: **A 61 K 9/06**
A 61 K 47/00

22) Date of filing: 22.06.83

30) Priority: 23.06.82 JP 109016/82

43) Date of publication of application:
 04.01.84 Bulletin 84/1

64) Designated Contracting States:
 BE CH DE FR IT LI NL SE

71) Applicant: **SHIONOGI & CO., LTD.**
 12, Dosho-machi 3-chome Higashi-ku
 Osaka 541(JP)

72) Inventor: **Okamoto, Kunko**
 20-78, Sano-dai
 Izumisano-shi Osaka(JP)

72) Inventor: **Nishihara, Yoshitaka**
 47-3, Aoba-dai
 Izumi-shi Osaka(JP)

72) Inventor: **Takahara, Mitsunori**
 12-12, Chiyodadai-cho
 Kawachinagano-shi Osaka(JP)

74) Representative: **Vossius Vossius Tauchner Heunemann**
 Rauh
 Siebertstrasse 4 P.O. Box 86 07 67
 D-8000 München 86(DE)

54) **Corticosteroid topical preparation.**

57) A corticosteroid topical preparation which comprises a monoglyceride of a C₈-C₁₀ medium-chain fatty acid together with the active ingredient.

EP 0 097 374 A2

-2-

This invention relates to a corticosteroid topical preparation for treating inflammation. More particularly, it relates to a new anti-inflammatory preparation in the form of ointment, gel, emulsion, cream and the like. Specifically, it relates to a corticosteroid topical preparation which comprises a monoglyceride of a C_6-C_{10} medium-chain fatty acid together with the active ingredient.

In the field of corticosteroid topical preparations it has been an accepted notion that the manifestation of the therapeutic efficacy of the active ingredient mainly depends on such factors as the mixing state of the active ingredient in the base; e.g. the state of dispersing or dissolving, and the proportion, the affinity of the mixed composition to the skin, the absorption efficacy of the active ingredient through the skin and the like. These factors are intricately intertwined and affect

the manifestation of the therapeutic efficacy. Therefore, the design of such preparations will hardly depend on simple analyses.

In general, for instance, the active ingredient should be dissolved rather than dispersed in the base to achieve a good manifestation of the efficacy of the active ingredient. Excessive enhancing of the solubility, however, adversely affects the release of the active

-3-

ingredient from the base and reduces the therapeutic efficacy. Therefore, the base ingredients should be selected so as to suitably arrange the above factors and the proportions should be determined so as to design a preparation with high therapeutic efficacy. Additionally, it is also important to find a new base ingredient for the preparation of a preferred base by a simple procedure.

Under the above circumstances, the inventors have sought to formulate a topical preparation intensifying the efficacy of anti-inflammatory corticosteroids having a high degree of safety and stability and imparting a good feeling when applied to the skin. They finally discovered that a topical preparation containing a monoglyceride of a C_6-C_{10} medium-chain fatty acid most efficiently balances the dispersion or solubility of the active ingredient in the base with the release to the skin while also being in contact with other adjuvants. Additionally, they discovered that the preparation remarkably improves skin irritations and shows an excellent physical stability. Thus the present invention was accomplished.

Accordingly, the present invention provides a corticosteroid topical preparation for treating inflammation which comprises a monoglyceride of a C_6-C_{10} medium-chain fatty acid, especially a saturated fatty acid, together with the active ingredient.

The topical preparation of the present invention contains 0.01 - 2.00 weight percent (abbreviated as wt. % hereinafter) of a corticosteroid and 0.5 - 20 wt. % of monoglyceride of a C₆-C₁₀ medium-chain fatty acid as indispensable ingredients and may contain one or more of the following pharmacologically acceptable adjuvants.

- a. 1-15 wt. % of a primary, secondary or tertiary C₂-C₆ alcohol;
- b. 1-10 wt. % of a polyethylene glycol having a mean molecular weight of about 200-4000;
- c. 1-90 wt. % of an oily substance;
- d. 0.5-15 wt. % of a non-ionic surfactant; and
- e. water.

Additionally, the preparation may contain suitable amounts of stabilizing agents, solubilizing agents and the like.

Examples of the active ingredient, which is a corticosteroid of the present invention are betamethasone valerate, betamethasone dipropionate, alclometasone dipropionate, hydrocortisone acetate, dexamethasone, prednisolone, diflucortolone valerate, triamcinolone acetonide, fluocinonide, fluocinolone acetonide, beclometasone dipropionate and the like; preferred are betamethasone valerate, betamethasone dipropionate, alclometasone dipropionate, dexamethasone, triamcinolone acetonide,

fluocinonide and fluocinolone acetonide; most preferred are betamethasone valerate, betamethasone dipropionate and alclometasone dipropionate. A normally effective amount of the active ingredient as topical drug, namely, about 0.01-2.00 wt. %, preferably 0.05-1.0 wt. %, is contained in the preparation. Some antibiotics may be combined with the corticosteroid as the active ingredient.

Examples of the monoglyceride of the C_6 - C_{10} medium-chain fatty acid are monoglycerides of C_6 - C_{10} straight chain fatty acids, especially C_6 - C_{10} saturated fatty acids, more specifically glycerol monohexanoate, glycerol monooctanoate and glycerol monodecanoate. They are used alone or in combination. The proportion of the monoglyceride in the preparation is about 0.5-20 wt. %, preferably 2-15 wt. %, and depends on the solubility of the active ingredient; A low proportion is sufficient for corticosteroids having a high solubility in the monoglyceride, such as betamethasone valerate, betamethasone dipropionate and the like, but a high proportion is necessary for those having poor solubility, such as hydrocortisone acetate, alclometasone dipropionate and the like. The proportion should also depend on the kind and the amount of the further ingredients.

One kind of various pharmacologically acceptable adjuvants is a C_2 - C_6 primary, secondary or tertiary alcohol,

i.e. a straight or branched alcohol, such as ethanol, isopropanol, ethylene glycol, propylene glycol, triethylene glycol, 1,3-butanediol, 1,5-pentanediol, 1,6-hexanediol, glycerol, 1,2,6-hexanetriol and the like. The alcohol is contained in the preparation in a proportion of about 1-15 wt. %, preferably about 5-10 wt. %.

A further possible adjuvant, i.e. a polyethylene glycol/^{having} a mean molecular weight of about 200 to 4000, may be selected from polyethylene glycol 200, 300, 400, 600, 1000, 1500, 1540, 4000 and the like. These are employed in a proportion of about 1-10 wt. %, preferably about 2-5 wt. %, based on the ^{weight of the} final preparation. Polyethylene glycol is usually used in combination with an alcohol as mentioned above since polyethylene glycol alone does not sufficiently contribute to the efficacy of the active ingredient. Although the combination is well-known in the field of ointments, the mixture of the polyethylene glycol and the alcohol should not be used in such an excessive proportion as to cause the dissolution of the active ingredient, which leads to ^{the} so-called syneresis of the ointment. Addition of the above monoglyceride in a certain proportion prevents the syneresis and improves the stability and efficacy of the preparation.

A further pharmacologically acceptable ingre-

7-

dient is an oily substance. It is used for the purpose of adjusting the solubility of the active ingredient and the viscosity of the preparation and improving the feeling of the preparation when applied. Examples of this further ingredient are liquid higher alcohols (e.g. 2-hexyldecanol and 2-octyldecanol), solid higher alcohols (e.g. cetyl alcohol and stearyl alcohol), higher fatty acids (e.g. palmitic acid and stearic acid), esters (e.g. isopropyl myristate, 2-octyldodecyl myristate, diethyl sebacate and diisopropyl adipate), liquid, semi-solid or solid hydrocarbons (e.g. squalane, liquid paraffin, various kinds of paraffins, vaseline, micro-crystalline wax and ceresin), waxes (e.g. beeswax, spermaceti and carnauba wax), triglycerides of natural fatty acid (e.g. castor oil and olive oil), synthetic triglyceride, diglycerides, monoglycerides of higher fatty acid and the like.

The oily substance is generally used in a proportion of about 1-90 wt. % based on the preparation, while the choice and combination ratio of the oily substances as well as the proportion to the whole preparation weight depend on the kind of corticosteroid to be used, the preparation form and the kind of the monoglyceride of a C₆-C₁₀ medium-chain fatty acid to be used and its proportion. The proportion of the oily substance of the oily substance is, for example, about 5-90 wt. % for an ointment and about 1-50 wt. %, preferably 2-35 wt. %, for a cream.

for an emulsion and a cream.

An additional adjuvant may be a surfactant. Surfactants are useful for forming a desired dosage form

and obtaining fine and homogeneous dispersions, emulsions and miscellaneous preparations. ^{The surfactant} / may be selected from

the group of non-ionic surfactants causing little skin irritation. Such non-ionic surfactants include -

sorbitan fatty acid esters, sorbitol fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene fatty acid esters, polyoxyethylene alkyl ethers, polyoxyethylene hydrogenated castor oil derivatives, polyoxyethylene polyoxypropylene alkyl ethers and the like.

Specific examples thereof are sorbitan mono-laurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquistearate, polyoxyethylene sorbitan mono-laurate, polyoxyethylene mono-palmitate, polyoxyethylene sorbitan mono-stearate, polyoxyethylene sorbitan tri-stearate, polyoxyethylene sorbitan mono-oleate, polyoxyethylene sorbitan tri-oleate, polyoxyethylene sorbitol mono-laurate, polyoxyethylene sorbitol hexa-stearate, polyoxyethylene sorbitol tetra-oleate, polyoxyethylene lauryl ester, polyoxyethylene stearyl ester, polyoxyethylene oleyl ester, polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene stearyl ether, polyoxyethylene oleyl ether, polyoxyethylene

hexadecyl ether, propylene glycol mono-stearate, polyoxypropylene polyoxyethylene cetyl ether and the like. The surfactant / may be used alone or in a mixture in a proportion of about 0.5-15 wt. %, preferably about 1-10 wt. %, based on the preparation.

Stabilizing agents, including anti-oxidants, chelating agents, antiseptics, buffer agents and the like also may be used in a suitable amount if required.

Solubilizing agents (e.g. crotamiton and benzyl alcohol) may also be applied, if necessary.

A practical embodiment of the preparation of the present invention is shown below. Its ingredients are abbreviated as follows:

monoglyceride: a monoglyceride of a C_6-C_{10} medium-chain fatty acid;

alcohol: a primary, secondary or tertiary C_2-C_6 alcohol;

polyethylene glycol: a polyethylene glycol having a mean molecular weight of 200-4000;

surfactant: a non-ionic surfactant;

(1) Ointment 1

Corticosteroid

0.01-2.00 wt. %

Monoglyceride

1-20 wt. %

Surfactant

0.5-5 wt. %

Oily substance

the balance

- (2) Ointment 2
Corticosteroid 0.01-2.00 wt. %
Monoglyceride 1-15 wt. %
Alcohol 1-15 wt. %
Surfactant 0.5-5 wt. %
Oily substance the balance
- (3) Ointment 3
Corticosteroid 0.01-2.00 wt. %
Monoglyceride 1-15 wt. %
Polyethylene glycol 1-10 wt. %
Surfactant 0.5-5 wt. %
Oily substance the balance
- (4) Ointment 4
Corticosteroid 0.01-2.00 wt. %
Monoglyceride 1-15 wt. %
Alcohol and polyethylene glycol 1-10 wt. %
Surfactant 0.5-5 wt. %
Oily substance the balance
- (5) Cream 1
Corticosteroid 0.01-2.00 wt. %
Monoglyceride 1-20 wt. %
Surfactant 0.5-15 wt. %
Oily substance 2-35 wt. %
Water the balance

- (6) Cream 2
- | | |
|----------------|-----------------|
| Corticosteroid | 0.01-2.00 wt. % |
| Monoglyceride | 1-20 wt. % |
| Alcohol | 1-15 wt. % |
| Surfactant | 0.5-15 wt. % |
| Oily substance | 2-35 wt. % |
| Water | the balance |
- (7) Cream 3
- | | |
|---------------------|-----------------|
| Corticosteroid | 0.01-2.00 wt. % |
| Monoglyceride | 1-20 wt. % |
| Polyethylene glycol | 1-10 wt. % |
| Surfactant | 0.5-15 wt. % |
| Oily substance | 2-35 wt. % |
| Water | the balance |
- (8) Cream 4
- | | |
|---------------------------------|-----------------|
| Corticosteroid | 0.01-2.00 wt. % |
| Monoglyceride | 1-20 wt. % |
| Alcohol and polyethylene glycol | 1-10 wt. % |
| Surfactant | 0.5-15 wt. % |
| Oily substance | 2-35 wt. % |
| Water | the balance |

The above preparations are only some examples and should not limit the scope of the present invention. The above preparations may contain a stabilizing agent, a solubilizing agent and the like as noted

above.

The topical preparation of this invention may be prepared by usual methods for preparing topical preparations. Namely, the active ingredient is dissolved in the monoglyceride of a C_6-C_{10} medium-chain fatty acid which may be mixed with the above mentioned alcohols, polyethylene glycol and/or a part of the oily substance as described above. The solution or mixture is subjected to heating, mixing with other ajuvants, dispersing, emulsifying and the like according to the desired dosage form is then and/cooled to room temperature. Furthermore, a required amount of a stabilizing agent may be added, if desired.

The efficacy and safety of the objective preparation were evaluated through a vasoconstrictor assay and by a skin irritation test, respectively.

Efficacy and safety evaluation:

1. Efficacy by vasoconstrictor assay (Enclosed method)

Each fixed amount of a preparation according to the working examples and references is applied onto a commercially available adhesive test tape. The test tapes are applied to the test site of the forearm and the back of the healthy human subject and kept there for 4 hours. After removal of the test tapes, the blanching (intensity of vasoconstriction) on the test spot where the test tape was applied is observed for further 2 or 4

hours. The results are shown in Tables 1 and 2.

The figures in the tables are relative values for the blanching intensity of the spot, calculated on the assumption that the intensity of the spot treated with the corresponding reference preparation is 100 each. The value is proportional to the extent of vasoconstriction.

2. Safety proof by "closed patch" test (Skin irritation test)

Each fixed amount of the preparation (including the active ingredient, i.e. the corticosteroid) according to the working examples and the references is placed on a commercially available patch (Finn chamber (Trademark), Taisho Seiyaku Co., & Ltd.). The test tapes are applied to the test site of the back of a healthy human subject and maintained for 48 hours. The test tapes are removed and the reddish marks of the test spots (the intensity of the irritation to the skin) are observed after 0.5 and 24 hours. The scores of both observed spots are summed up and the results are shown in Tables 1 and 2.

The figures in the tables represent relative values from the working examples, calculated in that the intensity of the reddish irritation mark of the corresponding reference preparation is assumed to be 100 each. The value is proportion-

nal to the extent of skin irritation and inversely proportional to the degree of safety.




Table 1 (Ointment)

Test Preparation		Efficacy (Vasoconstriction)		Safety (Irritation)
Example No.	Reference	2nd Hour	4th Hour	
1 - 1	A	130	120	98
1 - 1	B	147	129	105
1 - 2	C	210	180	100
1 - 3	D	150	175	101
1 - 3	E	162	160	103
1 - 4	F	161	218	100
1 - 5	G	208	140	38
1 - 6	H	312	206	62

Table 2 (Cream)

Test Preparation		Efficacy (Vasoconstriction)		Safety (Irritation)
Example No.	Reference	2nd Hour	4th Hour	
2 - 1	I	275	255	114
	J	172	221	58
2 - 2	I	293	231	46
	K	185	207	64
	L	227	214	102
2 - 3	I	191	168	35
2 - 4	M	144	121	85
	N	149	118	101
2 - 5	M	127	108	40
	N	152	110	87
2 - 6	O	161	135	67

-16-

As noted in Tables 1 and 2, the preparations of the working examples are superior to the corresponding reference preparations. Thus, the present invention provides the preparations having high efficacy and safety. In other words, the present invention provides a process for improving the activity of a corticosteroid preparation which comprises adding a monoglyceride of a C₆-C₁₀ medium-chain fatty acid to the topical preparation.

The following examples are intended to illustrate practical embodiments. The values of the proportions in Tables 3-1, 3-2, 4-1, 4-2 and 4-3 are weight percent values.

Example 1 (Ointment)

Ointments are prepared as follows:

White vaseline is melted at 70-80°C, other ingredients are added thereto, and mixed homogeneously. The resultant mixture is cooled to room temperature to give the preparations in Tables 3-1 and 3-2.

Example 2 (Cream)

Creams are prepared as follows:

All ingredients except for water are mixed and heated, stirred and blended at 70-80°C. A specific amount of purified water is added thereto. The mixture is stirred, emulsified and cooled to room temperature to give the preparations in Tables 4-1, 4-2 and 4-3.

Table 3-1

Ingredient	Example No.			Reference				
	1-1	1-2	1-3	A	B	C	D	E
Betamethasone Dipropionate	0.064	0.06	0.05	0.064	0.064	0.06	0.05	0.05
Betamethasone Valerate								
Alclometasone Dipropionate								
Glycerol Monohexanoate		10.0	10.0					
Glycerol Monoctanoate	5.0				10.0			10.0
Glycerol Monodecanoate								
Glycerol Monostearate								
Sorbitan Monostearate	2.0		2.0					
Sorbiton Tristearate		2.0						
Propyleneglycol Monostearate								
Diisopropyl Adipate	5.0							
Paraffin Wax		2.0		10.0		10.0	10.0	
Liquid Paraffin				89.936	89.936	89.94	89.95	89.95
White Vaseline	87.936	85.94	87.95					

Table 3-2

Ingredient	Example No.			Reference		
	1-4	1-5	1-6	F	G	H
Bethamethasone Valerate						
Alclometasone Dipropionate	0.1	0.05	0.12	0.1	0.05	0.12
Dexamethasone						
Glycerol Monohexanoate	5.0	10.0	5.0			
Glycerol Monodecanoate						
Propylene Glycol		3.0	4.0		10.0	10.0
Polyethylene Glycol 300			2.0			5.0
Polyethylene Glycol 400	2.0					
Sorbitan Sesquistearate	2.0	2.0			2.0	2.0
Sorbitan Monooleate						
Polyethylene Glycol Monostearate			2.0			
Diethyl Sebacate	3.0					
White Beeswax		3.0	3.0	99.9	3.0	2.0
Plastibase (50W)*	87.9	81.95	84.88		84.95	80.88
White Vaseline						

*(Trademark)

a mixed base of polyethylene with liquid paraffin (Squibb & Sons Co., Ltd.)

0097374

Table 4-1

Ingredient	Example No.			Reference			
	2-1	2-2	2-3	I	J	K	L
Alclometasone Dipropionate	0.05	0.05	0.05	0.05	0.05	0.05	0.05
Glycerol Monohexanoate	12.0	6.0					
Glycerol Monooctanoate			14.0				
Glycerol Monodecanoate							6.0
Glycerol Monostearate				20.0			
Propylene Glycol				3.0			5.0
Polyoxyethylene (20) Cetyl Ether	5.0		6.0				
Polyoxyethylene (30) Stearyl Ester		5.0			5.0	5.0	
Polyoxyethylene Sorbitan Mono-Stearate			1.8				
Crotamiton							
Diisopropyl Adipate	5.0		4.0		10.0		
Diethyl sebacate	10.0	10.0				10.0	
Cetyl Alcohol		8.0	10.0	8.0	10.0	10.0	8.0
Liquid Paraffin				5.0			10.0
White Beeswax	5.0			5.0	5.0	5.0	10.0
White Vaseline		10.0	10.0	7.0			
Purified Water	63.0	61.0	54.0	52.0	70.0	70.0	60.95

Table 4-2

Ingredient	Example No.		Reference	
	2-4	2-5	M	N
Betamethasone Dipropionate	0.064	0.064	0.064	0.064
Glycerol Monoctanoate	3.5	2.5		
Glycerol Monodecanoate	1.5			5.0
Glycerol Monostearate				
Polyoxyethylene (20) Cetyl Ether	4.0	0.5	2.0	4.0
Sorbitan Monooleate		1.5		
Polyoxyethylene Sorbitan Mono-oleate		3.0		10.0
2-Octyldodecanol	10.0			7.0
2-Octyldodecyl Myristate	7.0	2.0	8.0	
Cetyl Alcohol			6.0	
Liquid Paraffin	10.0		15.0	10.0
White Vaseline	64.0	90.0	69.0	63.936
Purified Water				

Table 4-3

Ingredient	Example No.			Reference
	2-6	2-7	2-8	
Betamethasone Valerate	0.12			0.12
Dexamethasone		0.1		
Prednisolone			1.0	
Glycerol Mono-octanoate		4.0	16.0	
Glycerol Monodecanoate	8.0	1.0		
Polyoxyethylene (20) Cetyl Ether		4.0		2.0
Polyoxyethylene (30) Stearyl Ester	4.5			
Sorbitan Sesquistearate	1.0		5.0	
Polyoxyethylene Sorbitan Mono-stearate				
Crotamiton			1.8	
Diethyl Sebacate		2.0		8.0 6.0 15.0 69.0
2-Octyldodecyl Myristate		8.0		
Cetyl Alcohol	10.0	8.0	10.0	
Liquid Paraffin	7.5			
White Vaseline	10.0	12.0	10.0	
Purified Water	59.0	61.0	56.0	

What we claim is:

1. A corticosteroid topical preparation which comprises a monoglyceride of a C_6-C_{10} medium-chain fatty acid together with the active ingredient.

2. The preparation claimed in Claim 1, wherein the preparation contains 0.01-2.00 weight percent of a corticosteroid and 0.5-20.0 weight percent of a monoglyceride of a C_6-C_{10} medium-chain fatty acid.

3. The preparation claimed in Claim 2, wherein one or more of the following additives are contained in addition to the corticosteroid and the monoglyceride:

a. 1-15 wt. percent of a primary, secondary or tertiary C_2-C_6 alcohol;

b. 1-10 wt. percent of a polyethylene glycol having a mean molecular weight of 200 to 4000;

c. 1-90 wt. percent of an oily substance;

d. 0.5-15 wt. percent of a non-ionic surfactant; and

e. water.

4. The preparation claimed in Claim 1, wherein the preparation contains 0.01-2.00 weight percent of a corticosteroid and 1-15 weight percent of a monoglyceride of a C_6-C_{10} medium-chain fatty acid.

5. The preparation claimed in Claim 3, wherein the preparation contains 0.5-5 wt. percent of a surfactant and an oily substance.

6. The preparation claimed in Claim 1, wherein the preparation contains 0.5-15 wt. percent of a surfactant, 2-35 wt. percent of an oily substance and water.

7. The preparation claimed in Claim 3, wherein the preparation contains 1-15 wt. percent of an alcohol, 0.5-15 wt. percent of a surfactant, 2-35 wt. percent of an oily substance and water.

8. The preparation claimed in Claim 3, wherein the preparation contains 1-10 wt. percent of a polyethylene glycol, 0.5-15 wt. percent of a surfactant, 2-35 wt. percent of an oily substance and water.

9. The preparation claimed in Claim 4, wherein the preparation contains 1-15 wt. percent of an alcohol, 0.5-5 wt. percent of a surfactant and an oily substance.

10. The preparation claimed in Claim 4, wherein the preparation contains 1-10 wt. percent of a polyethylene glycol, 0.5-5 wt. percent of a surfactant and an oily substance.

11. The preparation claimed in Claim 4, wherein the preparation contains 1-10 wt. percent of an alcohol and a polyethylene glycol, 0.5-5 wt. percent of a surfactant and an oily substance.

12. The preparation claimed in Claim 4, wherein a solubilizing agent is contained in addition to the corticosteroid and the monoglyceride.

13. The preparation claimed in Claim 1,

wherein the corticosteroid is selected from the group consisting of betamethasone valerate, betamethasone dipropionate, alclometasone dipropionate, dexamethasone, triamcinolone acetonide, fluocinonide and fluocinolone acetonide.

14. The preparation claimed in Claim 1, wherein the corticosteroid is selected from the group consisting of betamethasone valerate, betamethasone dipropionate and alclometasone dipropionate.

15. The preparation claimed in Claim 1, wherein the monoglyceride is selected from the group consisting of glycerol monohexanoate, glycerol mono-octanoate and glycerol monodecanoate.

16. A process for the production of a corticosteroid topical preparation with an improved activity which comprises adding a monoglyceride of a C_6-C_{10} medium-chain fatty acid together with the active ingredient to the topical preparation.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.